Since NIR laser adjuvant has the ability to safely induce selective signaling and activation of the cross-presenting CD103+ DC subpopulation [36, 37], which is known to prime cytotoxic T cells against tumors [86, 87] and orchestrate trafficking of effector T cells into the tumor microenvironment [88], it holds a potential to be broadly combined with cancer therapy to augment the anti-cancer immune response. The gene discussed is ITGAE; the disease is cancer.